CoChat
Sign Up
Cited by 365Systemic Lupus Erythematosus ResearchVenous Thromboembolism Diagnosis and ManagementBlood Coagulation and Thrombosis Mechanisms

The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.

Antiphospholipid antibodies and venous thromboembolism

Ginsberg, JS, Wells, PS, Brill-Edwards, P, Donovan, D, Moffatt, K, Johnston, M, Stevens, P, Hirsh, J·1995·Blood
DOI 10.1182/blood.v86.10.3685.bloodjournal86103685
Open this paper in CoChat — free account

Abstract

The clinical relevance of antiphospholipid antibodies (APLA) in patients without systemic lupus erythematosus who have venous thromboembolism (VTE) in unknown. Limited evidence suggests that there is an association between the presence of APLA and both initial and recurrent episodes of VTE and that patients with APLA and VTE are resistant to warfarin therapy. Unselected patients with a first episode of clinically suspected deep vein thrombosis or pulmonary embolism were evaluated with objective tests for VTE and with laboratory tests for APLA; the latter included tests for the lupus anticoagulant (LA) and anticardiolipin antibodies (ACLA). Patients with VTE were treated with anticoagulant therapy and observed during and after discontinuation of anticoagulants for symptomatic recurrence of VTE. There was a strong association between LA and VTE (odds ratio, 9.4; 95% confidence interval [CI], 2.1 to 46.2) and 9 to 65 (14%; 95% CI, 7% to 25%) patients with VTE had LA. There was no association between the presence of ACLA and VTE (odds ratio, 0.7; 95%CI, 0.3 to 1.7) because of the high frequency of positive ACLA assays in patients without VTE. None of the 16 patients with VTE and APLA developed recurrent VTE while receiving warfarin therapy. There was no difference in rates of recurrent VTE in patients with or without APLA after anticoagulant therapy was discontinued. The strong association between LA and VTE suggests that testing for LA in patients with VTE is useful. The measurement of ACLA in patients with VTE has no clinical usefulness because the results are abnormal in a high proportion of patients without VTE. Although the presence of APLA in patients with VTE was not associated with resistance to a conventional intensity of warfarin or an increased risk of recurrent VTE after discontinuation of warfarin, a larger study should address these issues in a subgroup of patients with VTE and LA.

Overview

Integrity signals

Registry

Crossref · 10.1182/blood.v86.10.3685.bloodjournal86103685

Cites

51 of 51 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Cited by

Sorted by citations

See all 365

Related

See all

Metadata

Authors
Ginsberg, J., Wells, P., Brill-Edwards, P., Donovan, D., Moffatt, K., Johnston, M., Stevens, P., & Hirsh, J.
Affiliations
McMaster University (CA)
ORCID
Hirsh, J
Venue
Blood
Publisher
American Society of Hematology
Published
1995-11-15
Volume
86
Issue
10
Pages
3685-3691
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
DOI
10.1182/blood.v86.10.3685.bloodjournal86103685
OpenAlex
W2157778986
Cited by
365
References
51
Citations by year
2026: 1 · 2025: 2 · 2024: 3 · 2023: 3 · 2022: 3 · 2021: 7 · 2020: 4 · 2019: 7 · 2018: 2 · 2017: 4 · 2016: 4 · 2015: 4 · 2014: 8 · 2013: 7 · 2012: 7
FWCI
14.59
Type
journal article
Language
en
Open access
closed
Locations
  • Blood (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Rheumatology › Systemic Lupus Erythematosus Research
  • Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
  • Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
Keywords
antiphospholipid antibodies, venous thromboembolism, lupus anticoagulant, anticardiolipin antibodies, deep vein thrombosis, pulmonary embolism, recurrent venous thromboembolism, warfarin resistance, anticoagulation, systemic lupus erythematosus
MeSH terms
Adolescent, Adult, Aged, Aged, 80 and over, Anticoagulants, Autoimmune Diseases, Female, Humans, Male, Middle Aged, Ontario, Predictive Value of Tests, Prospective Studies, Pulmonary Embolism, Thrombophlebitis, Warfarin, Lupus Coagulation Inhibitor, Antiphospholipid Syndrome, Antibodies, Antiphospholipid, Antibodies, Anticardiolipin

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review